Dermavant Sciences’ $200 Million Financing

VISCHER acted as Swiss counsel to Dermavant in the transaction.

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, entered into a USD 160m revenue interest purchase and sale agreement for its investigational product tapinarof with three participants that include Marathon Asset Management, NovaQuest Capital Management and a third institutional investor located in Boston.

The company concurrently entered into a USD 40m senior secured credit facility with the Boston-based firm. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream being investigated for the treatment of plaque psoriasis and atopic dermatitis.

The Vischer team included Adrian Dörig (Picture), Ruben Masar, Philipp Flückiger, Delia Fehr-Bosshard, Christoph Niederer and Patrik Fisch.

Involved fees earner: Adrian Dörig – VISCHER AG; Delia Fehr-Bosshard – VISCHER AG; Patrik Fisch – VISCHER AG; Philipp Flückiger – VISCHER AG; Ruben Masar – VISCHER AG; Christoph Niederer – VISCHER AG;

Law Firms: VISCHER AG;

Clients: Dermavant Sciences;

Author: Federica Tiefenthaler